10月15日，Tempus AI盘前下跌5.11%，报64.9692美元/股，成交额395.53万美元。
消息面上，公司此前宣布扩展与Moderna及Merck的多年合作，以支持个体化癌症疗法intismeran autogene的潜在商业化，但财务条款未披露，利好对股价提振有限。
与此同时，CEO兼董事长Eric Lefkofsky近期连续披露减持与拟减持安排，包括9月22日减持726406股、此前亦多次申报出售股份，内部人卖压担忧仍在发酵，成为当前股价承压的更直接因素。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.